Jonathan S. Berek

Publications

• Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO--The MIMOSA Study. Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, Del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J. J Clin Oncol. 2013; 31 (12): 1554-61
• Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study. Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, Berek JS, Manson JE. Obstet Gynecol. 2013; 121 (4): 709-716
• Cancer of the ovary, fallopian tube, and peritoneum. Berek JS, Crum C, Friedlander M. Int J Gynaecol Obstet. 2012: 119 Suppl 2 S118-29
• Current management of vulvar cancer. Fuh KC, Berek JS. Hematol Oncol Clin North Am. 2012; 26 (1): 45-62
• FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage. Chung YM, Park SH, Tsai WB, Wang SY, Ikeda MA, Berek JS, Chen DJ, Hu MC. Nat Commun. 2012: 3 1000
• Personalizing CA125 levels for ovarian cancer screening. Dorigo O, Berek JS. Cancer Prev Res (Phila). 2011; 4 (9): 1356-9
• Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy: Recommendations Based on Risk of Ovarian Cancer. Berek JS, Obstet Gynecol. 2011; 117 (2 Pt 1): 404
• Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Berek JS, Chalas E, Edelson M, Moore DH, Burke WM, Cliby WA, Berchuck A. Obstet Gynecol. 2010; 116 (3): 733-43
• Strategies and goals: the future of the International Gynecologic Cancer Society: IGCS Presidential Address. Berek JS, Int J Gynecol Cancer. 2010; 20 (9): 1434-9
• Lymph node-positive stage IIIC ovarian cancer: a separate entity? Berek JS, Int J Gynecol Cancer. 2009: 19 Suppl 2 S18-20
• Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. J Clin Oncol. 2009; 27 (3): 418-25
• Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE. Obstet Gynecol. 2009; 113 (5): 1027-37
• Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience. Markman M, Brady M, Hutson A, Berek JS. Int J Gynecol Cancer. 2009; 19 (2): 223-9
• CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Berek JS, Taylor PT, Nicodemus CF. J Immunother. 2008 Feb-Mar; 31 (2): 207-14
• HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review. Karam A, Berek JS, Stenson A, Rao J, Dorigo O. Gynecol Oncol. 2008; 111 (3): 568-71
• Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K, Workman P. Gynecol Oncol. 2008; 108 (3): 652-7
• Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. Chan JK, Kapp DS, Cheung MK, Shin JY, Stieglitz D, Husain A, Teng NN, Berek JS, Osann K, Guo H. Am J Obstet Gynecol. 2008; 198 (2): 216.e1-5
• Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Ueda SM, Kapp DS, Cheung MK, Shin JY, Osann K, Husain A, Teng NN, Berek JS, Chan JK. Am J Obstet Gynecol. 2008; 198 (2): 218.e1-6
• Elective oophorectomy for benign gynecological disorders. Shoupe D, Parker WH, Broder MS, Liu Z, Farquhar C, Berek JS. Menopause. 2007 May-Jun; 14 (3 Pt 2): 580-5
• Association of lymphadenectomy and survival in stage I ovarian cancer patients. Chan JK, Munro EG, Cheung MK, Husain A, Teng NN, Berek JS, Osann K. Obstet Gynecol. 2007; 109 (1): 12-9
• CA125: megadaltons of novel opportunities. Dorigo O, Berek JS. Gynecol Oncol. 2007; 104 (3): 505-7
• Elective oophorectomy in the gynecological patient: when is it desirable? Parker WH, Shoupe D, Broder MS, Liu Z, Farquhar C, Berek JS. Curr Opin Obstet Gynecol. 2007; 19 (4): 350-4
• Impact of the human papilloma vaccine on cervical cancer. Chan JK, Berek JS. J Clin Oncol. 2007; 25 (20): 2975-82
• Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Chan JK, Kapp DS, Shin JY, Husain A, Teng NN, Berek JS, Osann K, Leiserowitz GS, Cress RD, O'Malley C. Obstet Gynecol. 2007; 109 (6): 1342-50
• Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. Chan JK, Urban R, Cheung MK, Shin JY, Husain A, Teng NN, Berek JS, Walker JL, Kapp DS, Osann K. Cancer. 2007; 109 (12): 2454-60
• Ovarian conservation at the time of hysterectomy for benign disease. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Clin Obstet Gynecol. 2007; 50 (2): 354-61
• Prognostic factors for uterine cancer in reproductive-aged women. Lee NK, Cheung MK, Shin JY, Husain A, Teng NN, Berek JS, Kapp DS, Osann K, Chan JK. Obstet Gynecol. 2007; 109 (3): 655-62
• Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women. Zhang M, Cheung MK, Shin JY, Kapp DS, Husain A, Teng NN, Berek JS, Osann K, Chan JK. Gynecol Oncol. 2007; 104 (2): 396-400
• The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Chan JK, Urban R, Hu JM, Shin JY, Husain A, Teng NN, Berek JS, Osann K, Kapp DS. Br J Cancer. 2007; 96 (12): 1817-22
• Vulvar melanoma: a multivariable analysis of 644 patients. Sugiyama VE, Chan JK, Shin JY, Berek JS, Osann K, Kapp DS. Obstet Gynecol. 2007; 110 (2 Pt 1): 296-301
• Progress in ovarian cancer research: proceedings of the 5th Biennial Ovarian Cancer Research Symposium. Disis ML, Rivkin SE, Baron A, Markman M, Connolly D, Ueland F, Kohn E, Trimble E, Berek JS. Int J Gynecol Cancer. 2006 Mar-Apr; 16 (2): 463-9
• An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. Bryan DN, Radbod R, Berek JS. Int J Gynecol Cancer. 2006 Jan-Feb; 16 (1): 125-34
• 10th Biennial Helene Harris Memorial Trust meeting. Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND. Cancer Res. 2006; 66 (6): 2904-6
• Intraperitoneal chemotherapy for ovarian cancer. Hamilton CA, Berek JS. Curr Opin Oncol. 2006; 18 (5): 507-15
• Ovarian cancer in younger vs older women: a population-based analysis. Chan JK, Urban R, Cheung MK, Osann K, Shin JY, Husain A, Teng NN, Kapp DS, Berek JS, Leiserowitz GS. Br J Cancer. 2006; 95 (10): 1314-20
• Patterns and progress in ovarian cancer over 14 years. Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, Berek JS, Osann K. Obstet Gynecol. 2006; 108 (3 Pt 1): 521-8
• Response to commentaries on retention of the ovaries and long-term survival after hysterectomy. Parker WH, Broder MS, Liu Z, Shoupe Z, Farquhar C, Berek JS. Climacteric. 2006; 9 (5): 396-8; author reply 398-400
• Surgery for ovarian cancer: how to improve survival. Bristow RE, Berek JS. Lancet. 2006; 367 (9522): 1558-60
• The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Parthasarathy A, Cheung MK, Osann K, Husain A, Teng NN, Berek JS, Kapp DS, Chan JK. Gynecol Oncol. 2006; 103 (3): 1095-9
• Design, conduct and evaluation of a communication course for oncology fellows. Lenzi R, Baile WF, Berek J, Back A, Buckman R, Cohen L, Parker PA. J Cancer Educ. 2005; 20 (3): 143-9
• Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Muggia FM, Blessing JA, Waggoner S, Berek JS, Monk BJ, Sorosky J, Pearl ML. Gynecol Oncol. 2005; 96 (1): 108-11
• Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignancies. Elkas JC, Berek JS, Leuchter R, Lagasse LD, Karlan BY. Gynecol Oncol. 2005; 97 (2): 685-92
• Monoclonal antibody therapy of ovarian cancer. Nicodemus CF, Berek JS. Expert Rev Anticancer Ther. 2005; 5 (1): 87-96
• Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Berek JS, Howe C, Lagasse LD, Hacker NF. Gynecol Oncol. 2005; 99 (1): 153-9
• Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Monk BJ, Wang J, Im S, Stock RJ, Peters WA, Liu PY, Barrett RJ, Berek JS, Souhami L, Grigsby PW, Gordon W, Alberts DS. Gynecol Oncol. 2005; 96 (3): 721-8
• Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. Nouriani M, Bahador A, Berek JS, Cheng JP, Chi DS, Cliby WA, Del Priore G, Dodson MK, Duggan BD, Gershenson DM, Lentz SE, Penson RT, Robinson WR, Rodriguez M, Roman LD, Yu MC, Zempolich K, Dubeau L. Clin Cancer Res. 2004; 10 (8): 2681-6
• Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Berek JS, Expert Opin Biol Ther. 2004; 4 (7): 1159-65
• Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF. J Clin Oncol. 2004; 22 (17): 3507-16
• Using fresh tissue dissection to teach human anatomy in the clinical years. Robinson AG, Metten S, Guiton G, Berek J. Acad Med. 2004; 79 (7): 711-6
• Cervical cancer: an opportunity to prevent and cure. Berek JS, Cancer J. 2003 Sep-Oct; 9 (5): 325-6
• Surgical resection of solitary brain metastasis from cervical cancer. Tajran D, Berek JS. Int J Gynecol Cancer. 2003 May-Jun; 13 (3): 368-70
• CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R. Int J Gynecol Cancer. 2003 Mar-Apr; 13 (2): 120-4
• The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. Elkas JC, Holschneider CH, Katz B, Li AJ, Louie R, McGonigle KF, Berek JS. Int J Gynecol Cancer. 2003 Mar-Apr; 13 (2): 138-41
• Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. Gold MA, Walker JL, Berek JS, Hallum AV, Garcia DJ, Alberts DS. Gynecol Oncol. 2003; 90 (2): 325-30
• Biologic and immunologic therapies for ovarian cancer. Berek JS, Schultes BC, Nicodemus CF. J Clin Oncol. 2003; 21 (10 Suppl): 168s-174s
• Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Orsulic S, Smyth J, Ursulic S. Eur J Cancer. 2003; 39 (13): 1818-27
• Lymphovascular and perineural invasion in the parametria: a prognostic factor for early-stage cervical cancer. Memarzadeh S, Natarajan S, Dandade DP, Ostrzega N, Saber PA, Busuttil A, Lentz SE, Berek JS. Obstet Gynecol. 2003; 102 (3): 612-9
• Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study. Fracasso PM, Blessing JA, Wolf J, Rocereto TF, Berek JS, Waggoner S. Gynecol Oncol. 2003; 90 (1): 177-80
• Progress in the management of gynecologic cancer: consensus summary statement. Cannistra SA, Bast RC, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L. J Clin Oncol. 2003; 21 (10 Suppl): 129s-132s
• Simplification of the new Bethesda 2001 classification system. Berek JS, Am J Obstet Gynecol. 2003; 188 (3 Suppl): S2-5; discussion S6-7
• Specific keynote: immunological therapy for ovarian cancer. Berek JS, Dorigo O, Schultes B, Nicodemus C. Gynecol Oncol. 2003; 88 (1 Pt 2): S105-9; discussion S110-3
• FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Memarzadeh S, Holschneider CH, Bristow RE, Jones NL, Fu YS, Karlan BY, Berek JS, Farias-Eisner R. Int J Gynecol Cancer. 2002 Sep-Oct; 12 (5): 454-8
• Advances in the management of epithelial ovarian cancer. Memarzadeh S, Berek JS. J Reprod Med. 2001; 46 (7): 621-9; discussion 629-30
• Ovarian cancer: epidemiology, biology, and prognostic factors. Holschneider CH, Berek JS. Semin Surg Oncol. 2000 Jul-Aug; 19 (1): 3-10
• [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Lück HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Thigpen JT, Tropé C, Tuxen MK, Vergote I, Vermorken JB, Willemse PH. Gynecol Obstet Fertil. 2000 Jul-Aug; 28 (7-8): 576-83
• A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: a case report and review of the literature. Ghosh K, Dorigo O, Bristow R, Berek J. J Am Coll Surg. 2000; 191 (2): 212-5
• Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W, Alberts DS. J Clin Oncol. 2000; 18 (8): 1606-13
• Fraud. What is the evidence? Berek J, Gutierrez N, Stone J, Testa L. Care Manag J. 2000; 2 (1): 44-53
• Interferon plus chemotherapy for primary treatment of ovarian cancer. Berek JS, Lancet. 2000; 356 (9223): 6-7
• Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125. Berek JS, Gynecol Oncol. 2000; 77 (2): 225-6
• Advanced epithelial ovarian cancer: 1998 consensus statements. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Lück HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Willemse PH. Ann Oncol. 1999: 10 Suppl 1 87-92
• Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future? Hamilton TC, Berek JS, Kaye SB. Ann Oncol. 1999: 10 Suppl 1 69-73
• Endometrial cancer: recent developments in evaluation and treatment. Chen LM, McGonigle KF, Berek JS. Oncology (Williston Park). 1999; 13 (12): 1665-70; discussion 1675-8, 1681-2
• IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. Horton HM, Dorigo O, Hernandez P, Anderson D, Berek JS, Parker SE. J Immunol. 1999; 163 (12): 6378-85
• Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. Berek JS, Markman M, Blessing JA, Kucera PR, Nelson BE, Anderson B, Hanjani P. Gynecol Oncol. 1999; 74 (1): 48-52
• Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study. Berek JS, Markman M, Stonebraker B, Lentz SS, Adelson MD, DeGeest K, Moore D. Gynecol Oncol. 1999; 75 (1): 10-4
• Recurrent mature cystic teratoma presenting as a perihepatic mass. Chen L, Nelson SD, Berek JS. Obstet Gynecol. 1999; 94 (5 Pt 2): 856
• Surgery during chemotherapy and at relapse of ovarian cancer. Berek JS, Tropé C, Vergote I. Ann Oncol. 1999: 10 Suppl 1 3-7
• A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study. Feun LG, Blessing JA, Major FJ, DiSaia PJ, Alvarez RD, Berek JS. Gynecol Oncol. 1998; 71 (3): 410-5
• Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model. Dorigo O, Shawler DL, Royston I, Sobol RE, Berek JS, Fakhrai H. Gynecol Oncol. 1998; 71 (2): 204-10
• Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancer. Kim YB, Ghosh K, Ainbinder S, Berek JS. Cancer Treat Res. 1998: 95 253-76
• Progress in ovarian cancer. Chen LM, Berek JS. Curr Opin Obstet Gynecol. 1998; 10 (1): 51-5
• Psammocarcinoma with an aggressive course. Poggi SH, Bristow RE, Nieberg RK, Berek JS. Obstet Gynecol. 1998; 92 (4 Pt 2): 659-61
• Reducing loss-to-follow-up among women with abnormal Pap smears. Results from a randomized trial testing an intensive follow-up protocol and economic incentives. Marcus AC, Kaplan CP, Crane LA, Berek JS, Bernstein G, Gunning JE, McClatchey MW. Med Care. 1998; 36 (3): 397-410
• Gene therapy for ovarian cancer: development of novel treatment strategies. Dorigo O, Berek JS. Int J Gynecol Cancer. 1997; 7 (1): 1-13
• Complete debulking of epithelial ovarian cancer. Berek JS, Cancer J Sci Am. 1996 May-Jun; 2 (3): 132-3
• Dysgerminoma: the role of conservative surgery. Casey AC, Bhodauria S, Shapter A, Nieberg R, Berek JS, Farias-Eisner R. Gynecol Oncol. 1996; 63 (3): 352-7
• Evidence for a unifocal origin in familial ovarian cancer. Gallion HH, Guarino A, DePriest PD, van Nagell JR, Vaccarello L, Berek JS, Pieretti M. Am J Obstet Gynecol. 1996; 174 (4): 1102-6; discussion 1106-8
• Mixed mesodermal sarcoma of the ovary in a young patient. Fowler JM, Nathan L, Nieberg RK, Berek JS. Eur J Obstet Gynecol Reprod Biol. 1996; 65 (2): 249-53
• Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma. Kim YB, Berek JS, Martinez-Maza O, Satyaswaroop PG. Gynecol Oncol. 1996; 61 (1): 97-100
• Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J. J Clin Oncol. 1995; 13 (7): 1589-99
• Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum on Ovarian Cancer, May 4-7, 1995, Glasgow, UK. Sharp F, Blackett AD, Leake RE, Berek JS. Int J Gynecol Cancer. 1995; 5 (6): 449-458
• Interval debulking of ovarian cancer--an interim measure. Berek JS, N Engl J Med. 1995; 332 (10): 675-7
• Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial. Braly PS, Berek JS, Blessing JA, Homesley HD, Averette H. Gynecol Oncol. 1995; 56 (2): 164-8
• Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Berek JS, Bast RC. Cancer. 1995; 76 (10 Suppl): 2092-6
• Ovarian cancer spread: is laparoscopy to blame? Berek JS, Lancet. 1995; 346 (8969): 200
• Radiation therapy for adenocarcinoma of the uterine cervix: does the histology matter? Berek JS, Int J Radiat Oncol Biol Phys. 1995; 32 (5): 1543-4
• Surgical management of ovarian cancer. Farias-Eisner R, Kim YB, Berek JS. Semin Surg Oncol. 1994 Jul-Aug; 10 (4): 268-75
• A multicenter study of laparoscopic management of selected cystic adnexal masses in postmenopausal women. Parker WH, Levine RL, Howard FM, Sansone B, Berek JS. J Am Coll Surg. 1994; 179 (6): 733-7
• Advances in the biology of gynecologic cancer. Gotlieb WH, Berek JS. Curr Opin Oncol. 1994; 6 (5): 513-8
• Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1-2N0-1M0) disease. Farias-Eisner R, Cirisano FD, Grouse D, Leuchter RS, Karlan BY, Lagasse LD, Berek JS. Gynecol Oncol. 1994; 53 (1): 55-8
• Cytokine-induced modulation of tumor suppressor gene expression in ovarian cancer cells: up-regulation of p53 gene expression and induction of apoptosis by tumor necrosis factor-alpha. Gotlieb WH, Watson JM, Rezai A, Johnson M, Martínez-Maza O, Berek JS. Am J Obstet Gynecol. 1994; 170 (4): 1121-8; discussion 1128-30
• Fine-needle aspiration cytology in the management of gynecologic oncology patients. Layfield LJ, Berek JS. Cancer Treat Res. 1994: 70 1-13
• Laparoscopic management of the adnexal mass. Parker WH, Berek JS. Obstet Gynecol Clin North Am. 1994; 21 (1): 79-92
• Management of Selected Adnexal Masses in Postmenopausal Women by Operative Laparoscopy-A Multicentered Study Parker WH, Levine RL, Howard FM, Sansone B, Berek JS. J Am Assoc Gynecol Laparosc. 1994; 1 (4, Part 2): S27
• Molecular and biologic factors in the pathogenesis of ovarian cancer. Berek JS, Martínez-Maza O. J Reprod Med. 1994; 39 (4): 241-8
• Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts in pelvic and inguinal lymph nodes. Casey AC, Berek JS. Obstet Gynecol. 1994; 84 (4 Pt 2): 724-6
• Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal carcinomatosis. Fowler JM, Nieberg RK, Schooler TA, Berek JS. Int J Gynecol Cancer. 1994; 4 (1): 43-51
• Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Parker WH, Berek JS. Obstet Gynecol. 1994; 84 (5): 897
• Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group pilot study. Broun ER, Belinson JL, Berek JS, McIntosh D, Hurd D, Ball H, Williams S. Gynecol Oncol. 1994; 54 (2): 142-6
• The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS. Am J Obstet Gynecol. 1994; 170 (4): 974-9; discussion 979-80
• The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Farias-Eisner R, Teng F, Oliveira M, Leuchter R, Karlan B, Lagasse LD, Berek JS. Gynecol Oncol. 1994; 55 (1): 108-10
• Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Parker WH, Fu YS, Berek JS. Obstet Gynecol. 1994; 83 (3): 414-8
• Advanced epithelial ovarian cancer: 1993 consensus statements. Allen DG, Baak J, Belpomme D, Berek JS, Bertelsen K, ten Bokkel Huinink WW, van der Burg ME, Calvert AH, Conte PF, Dauplat J. Ann Oncol. 1993: 4 Suppl 4 83-8
• Advanced ovarian cancer. Tumour markers. Rustin GJ, van der Burg ME, Berek JS. Ann Oncol. 1993: 4 Suppl 4 71-7
• Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Lidor YJ, Xu FJ, Martínez-Maza O, Olt GJ, Marks JR, Berchuck A, Ramakrishnan S, Berek JS, Bast RC. Exp Cell Res. 1993; 207 (2): 332-9
• Current management of invasive squamous carcinoma of the vulva. Farias-Eisner R, Berek JS. Clin Geriatr Med. 1993; 9 (1): 131-43
• Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Watson JM, Berek JS, Martínez-Maza O. Gynecol Oncol. 1993; 49 (1): 8-15
• Impact of contraception on gynecologic cancers. Herbst AL, Berek JS. Am J Obstet Gynecol. 1993; 168 (6 Pt 2): 1980-5
• Molecular and biological factors in the pathogenesis of ovarian cancer. Berek JS, Martínez-Maza O, Hamilton T, Tropé C, Kaern J, Baak J, Rustin GJ. Ann Oncol. 1993: 4 Suppl 4 3-16
• Primary leiomyosarcoma of the ovary in a perimenarchal female. Monk BJ, Nieberg R, Berek JS. Gynecol Oncol. 1993; 48 (3): 389-93
• Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study) Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS, Jahshan A, Mortel R. Gynecol Oncol. 1993; 49 (3): 279-83
• Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype. Safrit JT, Berek JS, Bonavida B. Gynecol Oncol. 1993; 48 (2): 214-20
• Solitary recurrent metastasis of epithelial ovarian cancer in the spleen. Farias-Eisner R, Braly P, Berek JS. Gynecol Oncol. 1993; 48 (3): 338-41
• Biologic and immunologic therapy of ovarian cancer. Bookman MA, Berek JS. Hematol Oncol Clin North Am. 1992; 6 (4): 941-65
• Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon. Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley HD. Gynecol Oncol. 1992; 45 (1): 3-8
• Early-stage squamous cell and adenocarcinoma of the cervix. McGonigle KF, Berek JS. Curr Opin Obstet Gynecol. 1992; 4 (1): 109-19
• Improving adherence to screening follow-up among women with abnormal Pap smears: results from a large clinic-based trial of three intervention strategies. Marcus AC, Crane LA, Kaplan CP, Reading AE, Savage E, Gunning J, Bernstein G, Berek JS. Med Care. 1992; 30 (3): 216-30
• Intraperitoneal immunotherapy for ovarian cancer with alpha interferon. Berek JS, Eur J Cancer. 1992; 28A (4-5): 719-21
• Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Gotlieb WH, Abrams JS, Watson JM, Velu TJ, Berek JS, Martínez-Maza O. Cytokine. 1992; 4 (5): 385-90
• Second-look versus second-nature. Berek JS, Gynecol Oncol. 1992; 44 (1): 1-2
• Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast RC. Am J Obstet Gynecol. 1992; 166 (3): 997-1007
• Interleukin 6 and cancer treatment. Martínez-Maza O, Berek JS. In Vivo. 1991 Nov-Dec; 5 (6): 583-8
• A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer. Berek JS, Welander C, Schink JC, Grossberg H, Montz FJ, Zigelboim J. Gynecol Oncol. 1991; 40 (3): 237-43
• Adnexal torsion. An unusual cause of abdominal pain in postmenopausal women. Shih S, Vetto JT, Berek JS, Heaps JM, Hiatt JR. Am Surg. 1991; 57 (5): 327-9
• Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS, Jahshan A, Mortel R. Am J Obstet Gynecol. 1991; 164 (4): 997-1003; discussion 1003-4
• Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. Berek JS, Heaps JM, Fu YS, Juillard GJ, Hacker NF. Gynecol Oncol. 1991; 42 (3): 197-201
• Fine-needle aspiration cytology accuracy with palpable gynecologic neoplasms. Layfield LJ, Heaps JM, Berek JS. Gynecol Oncol. 1991; 40 (1): 70-3
• Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martínez-Maza O. Am J Obstet Gynecol. 1991; 164 (4): 1038-42; discussion 1042-3
• Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers. Nio Y, Zighelboim J, Berek JS, Bonavida B. Anticancer Res. 1990 Mar-Apr; 10 (2A): 441-6
• Adjuvant therapy for early-stage ovarian cancer. Berek JS, N Engl J Med. 1990; 322 (15): 1076-8
• Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Watson JM, Sensintaffar JL, Berek JS, Martínez-Maza O. Cancer Res. 1990; 50 (21): 6959-65
• Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells. Nio Y, Zighelboim J, Berek J, Bonavida B. Cancer Chemother Pharmacol. 1990; 26 (1): 1-8
• Cytoreductive surgery for advanced ovarian cancer: cardiovascular evaluation with pulmonary artery catheters. Eisner RF, Montz FJ, Berek JS. Gynecol Oncol. 1990; 37 (3): 311-4
• Intraperitoneal adoptive immunotherapy for peritoneal cancer. Berek JS, J Clin Oncol. 1990; 8 (10): 1610-2
• Malignant neoplasms arising in endometriosis. Heaps JM, Nieberg RK, Berek JS. Obstet Gynecol. 1990; 75 (6): 1023-8
• Management of selected cystic adnexal masses in postmenopausal women by operative laparoscopy: a pilot study. Parker WH, Berek JS. Am J Obstet Gynecol. 1990; 163 (5 Pt 1): 1574-7
• Ovarian metastases are rare in stage I adenocarcinoma of the cervix. Brown JV, Fu YS, Berek JS. Obstet Gynecol. 1990; 76 (4): 623-6
• Pathophysiology and management of endometrial hyperplasia and carcinoma. Fu YS, Gambone JC, Berek JS. West J Med. 1990; 153 (1): 50-61
• Pelvic hemangiopericytomas: a report of five cases and literature review. Muñoz AK, Berek JS, Fu YS, Heintz PA. Gynecol Oncol. 1990; 36 (3): 380-2
• Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer. A Gynecologic Oncology Group study. McGuire WP, Blessing JA, Berek JS, Munoz A. Invest New Drugs. 1990; 8 (2): 191-4
• Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. Lichtenstein A, Berenson J, Gera JF, Waldburger K, Martinez-Maza O, Berek JS. Cancer Res. 1990; 50 (22): 7364-70
• Risk factors for the development of lymph node metastasis in vulvar squamous cell carcinoma. Binder SW, Huang I, Fu YS, Hacker NF, Berek JS. Gynecol Oncol. 1990; 37 (1): 9-16
• Surgical staging of cervical cancer. Heaps JM, Berek JS. Clin Obstet Gynecol. 1990; 33 (4): 852-62
• Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Heaps JM, Fu YS, Montz FJ, Hacker NF, Berek JS. Gynecol Oncol. 1990; 38 (3): 309-14
• Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells. Bonavida B, Tsuchitani T, Zighelboim J, Berek JS. Gynecol Oncol. 1990; 38 (3): 333-9
• Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fractions on human ovarian tumor cells. Nio Y, Zighelboim J, Berek J, Bonavida B. Cancer. 1989; 64 (2): 434-41
• Human neutrophil-mediated lysis of ovarian cancer cells. Lichtenstein A, Seelig M, Berek J, Zighelboim J. Blood. 1989; 74 (2): 805-9
• Lymphocyte activation by recombinant interleukin-2 in ovarian cancer patients. Boyer PJ, Berek JS, Zighelboim J. Obstet Gynecol. 1989; 73 (5 Pt 1): 793-7
• Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. J Clin Oncol. 1989; 7 (4): 457-65
• Resection of diaphragmatic peritoneum and muscle: role in cytoreductive surgery for ovarian cancer. Montz FJ, Schlaerth JB, Berek JS. Gynecol Oncol. 1989; 35 (3): 338-40
• Screening, diagnosis, and monitoring of gynecologic malignancies. Montz FJ, Berek JS. Curr Opin Oncol. 1989; 1 (1): 75-81
• Synchronous primary neoplasms of the female reproductive tract. Eisner RF, Nieberg RK, Berek JS. Gynecol Oncol. 1989; 33 (3): 335-9
• Synergistic effect of combined intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian cancer model. Berek JS, Schink JC, Knox RM. Obstet Gynecol. 1989; 74 (4): 663-6
• Utilization of a murine model to optimize volume and dwell time of intraperitoneal cisplatin. Pretorius RG, Eisenkop S, Berek JS, Hacker NF, Ashikaga T, Knox RM, Lagasse LD. Gynecol Oncol. 1989; 34 (1): 66-9
• Vulvovaginal melanoma: report of seven cases and literature review. Brand E, Fu YS, Lagasse LD, Berek JS. Gynecol Oncol. 1989; 33 (1): 54-60
• Uterine corpus and cervical cancer. Berek JS, Hacker NF, Hatch KD, Young RC. Curr Probl Cancer. 1988 Mar-Apr; 12 (2): 61-131
• Controversies in the management of cervical adenocarcinoma. Brand E, Berek JS, Hacker NF. Obstet Gynecol. 1988; 71 (2): 261-9
• Immunologic control of ovarian cancer. Zighelboim J, Nio Y, Berek JS, Bonavida B. Nat Immun Cell Growth Regul. 1988; 7 (4): 216-25
• Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity. Lichtenstein A, Spina C, Berek JS, Jung T, Zighelboim J. Cancer Res. 1988; 48 (20): 5853-9
• Minimal cervical cancer: definition and histology. Fu YS, Berek JS. Recent Results Cancer Res. 1988: 106 47-56
• Peritoneal cytology of ovarian cancer patients receiving intraperitoneal therapy: quantitation of malignant cells and response. Sagae S, Berek JS, Fu YS, Chang N, Dauplat J, Hacker NF. Obstet Gynecol. 1988; 72 (5): 782-8
• Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Malkasian GD, Knapp RC, Lavin PT, Zurawski VR, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast RC, Ritts RE. Am J Obstet Gynecol. 1988; 159 (2): 341-6
• Sensitivity of fresh and cultured ovarian tumor cells to tumor necrosis factor, interferon-alpha 2, and OK-432. Nio Y, Zighelboim J, Berek JS, Bonavida B. Cancer Immunol Immunother. 1988; 27 (3): 246-54
• CA 125 for the monitoring of ovarian carcinoma during primary therapy. Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast RC. Obstet Gynecol. 1987; 69 (2): 223-7
• Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervix. Fu YS, Berek JS, Hilborne LH. Appl Pathol. 1987; 5 (1): 47-56
• Distant metastases in epithelial ovarian carcinoma. Dauplat J, Hacker NF, Nieberg RK, Berek JS, Rose TP, Sagae S. Cancer. 1987; 60 (7): 1561-6
• Intraperitoneal cis-platinum as salvage therapy for refractory epithelial ovarian cancer. Hacker NF, Berek JS, Pretorius RG, Zuckerman J, Eisenkop S, Lagasse LD. Obstet Gynecol. 1987; 70 (5): 759-64
• Prognostic significance of DNA ploidy and morphometric analyses of adenocarcinoma of the uterine cervix. Fu YS, Hall TL, Berek JS, Hacker NF, Reagen JW. Anal Quant Cytol Histol. 1987; 9 (1): 17-24
• Rhabdomyosarcoma of the uterine cervix. Sarcoma botryoides. Brand E, Berek JS, Nieberg RK, Hacker NF. Cancer. 1987; 60 (7): 1552-60
• Antitumor and immunologic effects of a pyridine-extracted fraction of Propionibacterium acnes. Lichtenstein A, Berek J. Cancer Immunol Immunother. 1986; 22 (1): 24-30
• CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Berek JS, Knapp RC, Malkasian GD, Lavin PT, Whitney C, Niloff JM, Bast RC. Obstet Gynecol. 1986; 67 (5): 685-9
• Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Heintz AP, Hacker NF, Berek JS, Rose TP, Munoz AK, Lagasse LD. Obstet Gynecol. 1986; 67 (6): 783-8
• Human papillomavirus deoxyribonucleic acid in adenocarcinoma and adenosquamous carcinoma of the uterine cervix. Smotkin D, Berek JS, Fu YS, Hacker NF, Major FJ, Wettstein FO. Obstet Gynecol. 1986; 68 (2): 241-4
• Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumors. Fu YS, Ro J, Reagan JW, Hall TL, Berek J. Obstet Gynecol. 1986; 67 (4): 478-82
• Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group Study. Thigpen JT, Blessing JA, Homesley HD, Berek JS, Creasman WT. Gynecol Oncol. 1986; 23 (1): 101-4
• The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, Mortel R, Whitney C, Zurawski VR, Bast RC. Am J Obstet Gynecol. 1986; 155 (1): 56-60
• Adenocarcinoma of the uterine cervix: histologic variables associated with lymph node metastasis and survival. Berek JS, Hacker NF, Fu YS, Sokale JR, Leuchter RC, Lagasse LD. Obstet Gynecol. 1985; 65 (1): 46-52
• Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. Berek JS, Knapp RC, Hacker NF, Lichtenstein A, Jung T, Spina C, Obrist R, Griffiths CT, Berkowitz RS, Parker L. Am J Obstet Gynecol. 1985; 152 (8): 1003-10
• Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD. Cancer Treat Rev. 1985: 12 Suppl B 23-32
• Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD. Cancer Res. 1985; 45 (9): 4447-53
• Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer. Lichtenstein AK, Berek J, Zighelboim J. J Natl Cancer Inst. 1985; 74 (2): 349-55
• Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model. Berek JS, Lichtenstein AK, Knox RM, Jung TS, Rose TP, Cantrell JL, Zighelboim J. Cancer Res. 1985; 45 (9): 4215-8
• Whole abdominal radiation as salvage therapy for epithelial ovarian cancer. Hacker NF, Berek JS, Burnison CM, Heintz PM, Juillard GJ, Lagasse LD. Obstet Gynecol. 1985; 65 (1): 60-6
• Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum. Lichtenstein A, Berek J, Bast R, Spina C, Hacker N, Knapp RC, Zighelboim J. J Biol Response Mod. 1984; 3 (4): 371-8
• Immunotherapy with biochemically dissociated fractions of Propionibacterium acnes in a murine ovarian cancer model. Berek JS, Cantrell JL, Lichtenstein AK, Hacker NF, Knox RM, Nieberg RK, Poth T, Elashoff RM, Lagasse LD, Zighelboim J. Cancer Res. 1984; 44 (5): 1871-5
• Individualization of treatment for stage I squamous cell vulvar carcinoma. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Leuchter RS. Obstet Gynecol. 1984; 63 (2): 155-62
• Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Berek JS, Bast RC, Lichtenstein A, Hacker NF, Spina CA, Lagasse LD, Knapp RC, Zighelboim J. Obstet Gynecol. 1984; 64 (5): 708-14
• Preoperative radiation therapy for locally advanced vulvar cancer. Hacker NF, Berek JS, Juillard GJ, Lagasse LD. Cancer. 1984; 54 (10): 2056-61
• Rectosigmoid colectomy and reanastomosis to facilitate resection of primary and recurrent gynecologic cancer. Berek JS, Hacker NF, Lagasse LD. Obstet Gynecol. 1984; 64 (5): 715-20
• Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice. Lichtenstein AK, Berek J, Kahle J, Zighelboim J. Cancer Res. 1984; 44 (11): 5118-23
• Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status. Berek JS, Hacker NF, Lagasse LD, Poth T, Resnick B, Nieberg RK. Obstet Gynecol. 1984; 64 (2): 207-12
• Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity. Lichtenstein AK, Kahle J, Berek J, Zighelboim J. J Immunol. 1984; 133 (1): 519-26
• Vaginal reconstruction performed simultaneously with pelvic exenteration. Berek JS, Hacker NF, Lagasse LD. Obstet Gynecol. 1984; 63 (3): 318-23
• Delayed vaginal reconstruction in the fibrotic pelvis following radiation or previous reconstruction. Berek JS, Hacker NF, Lagasse LD, Smith ML. Obstet Gynecol. 1983; 61 (6): 743-8
• Estrogen and progesterone receptors in ovarian neoplasms. Ford LC, Berek JS, Lagasse LD, Hacker NF, Heins Y, Esmailian F, Leuchter RS, DeLange RJ. Gynecol Oncol. 1983; 15 (3): 299-304
• Laparoscopy in the management of patients with ovarian carcinoma. Berek JS, Hacker NF. Clin Obstet Gynaecol. 1983; 10 (2): 213-22
• Microinvasive carcinoma of the vulva. Hacker NF, Berek JS, Lagasse LD, Nieberg RK. Obstet Gynecol. 1983; 62 (1): 134-5
• Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Pretorius RG, Hacker NF, Berek JS, Ford LC, Hoeschele JD, Butler TA, Lagasse LD. Cancer Treat Rep. 1983; 67 (12): 1085-92